The impact of biotechnology products on pharmaceutical industries and new therapeutics can be illustrated by the fact that a remarkable percentage of recent drug approvals by the FDA are in the biological category (recombinant proteins and peptides, monoclonal antibodies, etc.)
Inclusion criteria encompassed all studies employing in vitro models (e.g., fibroblast proliferation, keratinocyte migration, collagen synthesis assays), in vivo studies using animal models for wound healing assessments, clinical trials evaluating the efficacy and safety of tripeptides in human subjects, and studies utilizing molecular, biochemical, or histological analyses to determine the mechanisms of tripeptides in wound recovery
SLU-PP-332: the non-peptide agonist SLU-PP-332 illustrates the second strategy
Clinical protocols for switching specifically to CagriSema will likely be established after the treatment receives approval and enters clinical practice
stable for up to 60 days when reconstituted with bacteriostatic water [9]